72
Standard BioTools to sell Microfluidics business to ARCHIMED
Why it matters
Standard BioTools entered a definitive agreement to sell its Microfluidics business to ARCHIMED, expected to close in ~30 days. The filing does not disclose the sale price or relative revenue contribution of the unit, limiting confidence in quantifying the transaction's materiality to the overall business.
In plain language
Standard BioTools agreed to sell one of its business units (Microfluidics) to a healthcare investment firm. The deal should close within a month, but the filing doesn't say how much money is involved.
Exposure
LAB ·
Price check
not measured: no fresh price at the time of scoringHow this is measured
Information only. AURA does not give buy or sell recommendations.